From a clinical perspective, current therapeutic approaches face challenges of tissue-specific heterogeneity, as evidenced by the paradoxical effects of IL-17 inhibitors that benefit psoriasis but potentially exacerbate intestinal inflammation (64). The gene discussed is IL17A; the disease is psoriasis.